TAKANORI MATSUKI

Dr. TAKANORI MATSUKI

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MNMaiko Naito
Maiko Naito
YTYoshito Takeda
Yoshito Takeda
RERyuya Edahiro
Ryuya Edahiro
YSYuya Shirai
Yuya Shirai
TETakatoshi Enomoto
Takatoshi Enomoto
AKAtsushi Kumanogoh
Atsushi Kumanogoh
Nontuberculous mycobacterial pulmonary disease (NTM-PD), mainly caused by Mycobacterium avium complex (MAC), and pulmonary tuberculosis (TB) are emerging health problems worldwide. However, because their clinical features are often similar, it remains difficult to differentiate NTM-PD from TB when the diagnosis cannot be made by sputum culture. To investigate potential serum biomarkers, we conducted non-targeted proteome analysis on serum extracellular vesicles (EVs) collected from 10 patients with MAC pulmonary disease (MAC-PD), 7 patients with TB, and 10 healthy controls. A total of 2614 proteins were identified in the discovery cohort. The EV protein signature from patients with NTM-PD and TB reflected infectious diseases and inflammatory response pathways. Among the identified proteins, the expression of Na+/H+ exchanger regulatory factor 2 (NHERF2) was significantly elevated in patients with MAC-PD compared with healthy controls and patients with TB. Moreover, upregulation of NHERF2 was confirmed by immunoblotting of serum EVs and immunohistochemistry of lungs with mycobacterial infection. Our findings highlight that NHERF2 in serum EVs might be a potential biomarker for distinguishing MAC-PD from TB, possibly reflecting the pathogenesis of MAC-PD.

10 June 2025 in International Journal of Rheumatic Diseases
Verified
Journal Article
Open access
YHYuki Hara
Yuki Hara
TNTakuro Nii
Takuro Nii
TMTAKANORI MATSUKI
TAKANORI MATSUKI
KTKazuyuki Tsujino
Kazuyuki Tsujino
KMKeisuke Miki
Keisuke Miki
HKHiroshi Kida
Hiroshi Kida
Objectives: The aim of this study was to identify the risk factors for Pneumocystis jirovecii pneumonia (PCP) in patients with rheumatoid arthritis (RA) and to recommend appropriate disease‐modifying antirheumatic drug (DMARD) selection for those at high risk of developing PCP. Methods: We conducted a retrospective review of patients with RA who were treated with methotrexate or biologic and targeted synthetic DMARDs (b/tsDMARDs). Patients with no chest computed tomography data or those receiving prophylactic sulfamethoxazole–trimethoprim, atovaquone, or inhaled pentamidine were excluded. Results: Among 554 patients who met the inclusion and exclusion criteria, 16 developed PCP. Multivariate logistic analysis revealed interstitial pneumonia as a significant risk factor for PCP (odds ratio: 4.53, 95% confidence interval: 1.51–13.12), whereas salazosulfapyridine (SASP) use was associated with a reduced risk (odds ratio: 0.11, 95% confidence interval: 0.00–0.81). A Kaplan–Meier analysis comparing the cumulative incidence of PCP between propensity score‐matched SASP users and nonusers further demonstrated that SASP use reduced the risk of developing PCP. Conclusion: Patients with RA complicated by interstitial pneumonia are at a higher risk of developing PCP. Although methotrexate and b/tsDMARDs do not increase the risk of developing PCP, SASP may potentially reduce the risk. A prospective study is warranted to investigate the efficacy and safety of SASP in patients with RA at high risk for PCP.

18 January 2024 in Respiratory Investigation
Verified
Journal Article
Closed access
YNYuka Nagata
Yuka Nagata
KMKeisuke Miki
Keisuke Miki
RKRyo Kijima
Ryo Kijima
YMYasuhiro Mihashi
Yasuhiro Mihashi
SMSatoshi Miyamoto
Satoshi Miyamoto
HKHiroshi Kida
Hiroshi Kida

20 September 2024 in Respiratory Investigation
Verified
Journal Article
Closed access
SMSatoshi Miyamoto
Satoshi Miyamoto
KMKeisuke Miki
Keisuke Miki
SKSeigo Kitada
Seigo Kitada
YNYuka Nagata
Yuka Nagata
RKRyo Kijima
Ryo Kijima
HKHiroshi Kida
Hiroshi Kida

27 March 2026 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
AFAtsushi Funauchi
Atsushi Funauchi
KHKazuki Hashimoto
Kazuki Hashimoto
KFKiyoharu Fukushima
Kiyoharu Fukushima
YMYuki Matsumoto
Yuki Matsumoto
NHNanako Hamada
Nanako Hamada
HKHiroshi Kida
Hiroshi Kida
The nontuberculous mycobacteria (NTM) isolated from gastric aspirate have demonstrated >85% strain concordance with those from the sputum, suggesting that they originate from the lungs rather than the environment. Gastric aspirate, although not yet internationally recognized, may be a useful supplementary specimen for diagnosing NTM pulmonary disease.

24 April 2026 in International Immunology
Verified
Journal Article
Closed access
HNHiroshi Nabeshima
Hiroshi Nabeshima
KFKiyoharu Fukushima
Kiyoharu Fukushima
YLYu-Chen Liu
Yu-Chen Liu
DMDaisuke Motooka
Daisuke Motooka
TNTakayuki Niitsu
Takayuki Niitsu
SAShizuo Akira
Shizuo Akira
Pulmonary fibrosis has a poor prognosis due to challenges in early diagnosis and therapeutic intervention. Current treatments remain largely ineffective due to an incomplete understanding of the complex pathology, including the interactions between fibroblasts and profibrotic immune cells within fibrotic lungs. To elucidate the dynamics of fibrosis, we performed single-cell RNA sequencing (scRNA-seq) on bronchoalveolar lavage fluid (BALF) obtained from patients with interstitial lung disease (ILD). We identified the SPP1- and APOE-expressing macrophage population that is commonly present across ILDs. Histological analysis showed that this macrophage population accumulated at the center of fibrotic foci. Furthermore, the ratio of this macrophage population was increased in both progressive pulmonary fibrosis (PPF) and idiopathic pulmonary fibrosis (IPF). Transcriptomic analysis further divided this macrophage population into two subsets: SLC40A1+ or HAMP+ fibrosis-associated macrophages. We found that the relative balance of IL-10 and IL-8 regulated SLC40A1 and HAMP expression within fibrosis-associated macrophages. Additionally, histological analysis revealed that bronchial epithelium expressed IL-8, while type II alveolar epithelial cells expressed IL-10 in the fibrotic lung. SLC40A1+ fibrosis-associated macrophages localized to CD31+ perivascular regions and mediated the uptake and degradation of the hemoglobin–haptoglobin complex. This dual pathway—providing iron via SLC40A1 and intracellular iron accumulation via HAMP—facilitated the transition of fibroblasts into SPP1+ myofibroblasts. Moreover, ferroptotic fibroblasts secreted TGF-β1, which further contributes to fibrotic progression. In conclusion, aberrant iron metabolism orchestrated by fibrosis-associated macrophages may contribute to fibrosis by facilitating the transition of myofibroblasts. These findings provide mechanistic insight into the progression of autonomous pulmonary fibrosis.